

Figure S1. CPTH2, a histone acetyltransferase inhibitor; C646, a selective small molecule inhibitor of EP300/CBP; AU1, GSK1379725A, a BRD PHD finger transcription factor antagonist; HBS1, a high-affinity ligand of cysteine-histidine-rich region 1, an EP300/CBP inhibitor; RGFP966, an inhibitor of histone deacetylase 3; SF2523, a PI3K/BRD4 inhibitor; JQ1, a BET inhibitor; BDF1253, a BET inhibitor; PLX51107, a BET inhibitor; PPC, a BET inhibitor; OTX015, a BET inhibitor; AZD3965, an inhibitor of monocarboxylate transporter 1. CPTH2, cyclopentylidene-[4-(4-chlorophenyl)thiazol-2-yl]hydrazone; PPC, physachenolide C; C646, ChemBridge#5838646; EP300, E1A binding protein P300; CBP, CREB binding protein; BET, BRD and extraterminal; BRD, bromodomain protein.




PCC

CI







AZD3965